Challenges and opportunities in the assessment of measurable residual disease in multiple myeloma

British Journal of Haematology
Susan BalLuciano J Costa

Abstract

Treatment response assessment in multiple myeloma (MM) relies on the detection of paraprotein in serum and/or urine, bone marrow morphology and immunohistochemistry. With remarkable advances in therapy, particularly in the newly diagnosed setting, achievement of complete remission became frequent, creating the need to identify smaller amounts of residual disease and understand their prognostic and therapeutic implications. Measurable residual disease (MRD) can be assessed primarily by flow cytometry and next generation sequencing and state-of-the-art assays have sensitivity approaching 1 in 106 cells. This review discusses the existing challenges in utilizing MRD to inform management of MM and highlights open research questions and opportunities as MRD is more routinely incorporated into clinical practice for patients with MM.

References

Sep 1, 1987·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M PalmerM Koch
Jul 21, 2006·Leukemia·B G M DurieUNKNOWN International Myeloma Working Group
Mar 16, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruno PaivaJesus F San Miguel
Sep 2, 2011·Haematologica·Jesús F San-Miguel, María-Victoria Mateos
Nov 10, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David MarinLetizia Foroni
Dec 1, 2011·Blood·Bruno PaivaUNKNOWN PETHEMA/GEM (Programa para el Estudio de la Terapéutica en Hemopatías Malignas/Grupo Español de Mieloma) Cooperative Study G
May 11, 2012·The New England Journal of Medicine·Philip L McCarthyCharles Linker
Jun 5, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andy C RawstronRoger G Owen
Aug 13, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sally F BarringtonBruce D Cheson
Jun 20, 2015·Blood·Joaquín Martínez-LópezUNKNOWN Spanish Multiple Myeloma Group / Program for the Study of Malignant Blood Diseases Therapeutics (GEM / PETHEMA) Cooperative
Feb 18, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Pier Luigi ZinzaniAlessandro Levis
Apr 28, 2016·Blood·Bruno PaivaUNKNOWN Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas (GEM/PETHEMA) Cooperative Study G
Jun 23, 2016·The New England Journal of Medicine·Peter JohnsonSally Barrington
Aug 25, 2016·The New England Journal of Medicine·Antonio PalumboUNKNOWN CASTOR Investigators
Oct 6, 2016·The New England Journal of Medicine·Meletios A DimopoulosUNKNOWN POLLUX Investigators
Dec 14, 2016·Journal of the National Comprehensive Cancer Network : JNCCN·Arnel PalleraJerald P Radich
Dec 29, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Qian ShiDaniel J Sargent
Apr 6, 2017·The New England Journal of Medicine·Michel AttalUNKNOWN IFM 2009 Study
Apr 22, 2017·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Kenneth C AndersonElena Zamagni
May 13, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Juan-Jose LahuertaUNKNOWN GEM (Grupo Español de Mieloma)/PETHEMA (Programa para el Estudio de la Terapéutica en Hemopatías Malignas) Cooperative Study
Jul 9, 2017·Journal of the National Comprehensive Cancer Network : JNCCN·Margaret R O'DonnellNdiya Ogba
Jul 26, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Philip L McCarthyMichel Attal
Sep 26, 2017·Annals of Oncology : Official Journal of the European Society for Medical Oncology·H TakamatsuS Nakao
Dec 13, 2017·The New England Journal of Medicine·María-Victoria MateosUNKNOWN ALCYONE Trial Investigators

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Sequencing

Several sequencing approaches are employed to understand and examine tumor development and progression. These include whole genome as well as RNA sequencing. Here is the latest research on cancer sequencing.

Related Papers

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Andy C RawstronRoger G Owen
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Bruno PaivaGrupo Español de Mieloma (GEM)/Programa para el Estudio de la Terapéutica en Hemopatías Malignas (PETHEMA) cooperative study
Current Hematologic Malignancy Reports
Shalin KothariSarah A Holstein
International Journal of Laboratory Hematology
I V GaltsevaL P Mendeleeva
© 2021 Meta ULC. All rights reserved